
GlaxoSmithKline opens new £56 million facility in Hertfordshire
pharmafile | April 19, 2016 | News story | Manufacturing and Production | Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware
GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England.
The facility in Ware will create 150 new jobs and will form the new base for the pharma giant’s production of inhalers to use with respiratory medicines. Chief executive of GSK, Sir Andrew Witty, and life sciences minister, George Freeman MP, were given a tour of the facility which produces the Ellipta inhalers.
This is the latest investment in the Ware facility which formed part of a £200 million investment by GSK into its UK facilities.
Witty says: “This new facility demonstrates our commitment to manufacturing in the UK which continues to be a very positive environment for life sciences investment. We currently export Ellipta inhalers from Ware to over 74 countries and the new facility opened today will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide.”
Freeman added: “This £56 million investment by GSK is fantastic news for Ware and the UK’s thriving life sciences industry.”
Sean Murray
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …





